Andere talen MindBio Therapeutics Corp.

Aandelen

MBIO

CA60256C1086

Beurs gesloten - Canadian Securities Exchange Andere beurzen 15:30:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,04 ^CAD	0,00%		+14,29%	+60,00%

20/06	MindBio Therapeutics Corp. Rapporteert duurzaamheidsgegevens van Fase 2A klinische onderzoeken bij depressieve patiënten die MB22001 testen	CI
12/06	Mindbio Therapeutics rapporteert secundaire gegevens: Verbetering van psychologische resultaten & veiligheidsresultaten bij depressieve patiënten uit Fase 2A-depressiestudie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001	20/06
MindBio Therapeutics Reports Secondary Data, Improvement of Psychological Outcomes and Safety Results in Depressed Patients from Phase 2A Depression Trial	13/06
Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial	12/06
MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05
MindBio Therapeutics Scientists Present Landmark Women's Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month	03/05
Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3	02/05
MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials	01/05
MindBio Therapeutics Corp. Announces the Regulatory Approval of A Series of Clinical Trials in Women's Health Using MB22001	30/04
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry	24/04
MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	20/03
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	20/03
MindBio Therapeutics Receives Final Approval to Conduct Phase 2B Trial Microdosing Mb22001 in Patients With MDD	04/03
Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder	04/03
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	27/02
MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	26/02
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial	15/02
MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial	14/02
MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder	30/01
MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials	20/12
MindBio Therapeutics Corp. Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer	31-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MindBio Therapeutics Corp.

Aandelen

MBIO

CA60256C1086

Andere talen

Filters